SBIR/STTR Research Award
SBIR TOPIC 107 AFFINITY REAGENTS FOR THE IMMUNE SYSTEM OF GOLDEN HAMSTER
Award amount
$600,000Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- QOOLABS INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- K7HZKKAMVHK5
- Solicitation number
- PHS-2022-1
- Topic code
- 107
Research abstract
Syrian golden hamsters are valuable animal models for studying metabolic disease and human infectious diseases including SARS-CoV-2. However, the usefulness of the hamster as a small animal model for biomedical research has been constrained by the lack of immunological reagents. In this proposal, the Offeror proposes to develop affinity reagents for eight immune targets of Syrian golden hamsters that are relevant to SARS-CoV-2 infections and host immune responses, and to evaluate affinity and specificity of the produced antibodies using recombinant proteins and endogenous targets expressed by immune cells from hamsters. Successful completion of the proposed work will result in a comprehensive portfolio of antibodies that facilitate pre-clinical studies on SARS-CoV-2.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- AFFINITY REAGENTS FOR THE IMMUNE SYSTEM OF GUINEA PIGS IL1B, IL2, IL4, IL6, IL8, IL10, IL12, AND IL13.
- SBIR Topic 133: Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections
- Affinity Reagents for the Immune System of Golden Hamster (for SARS-CoV-2 induced long-COVID disease)
- Rapid at-home Detection for Serologic Status of Hepatitis C Virus (HCV) Infection
- SBIR TOPIC 107 MONOCLONAL ANTIBODIES FOR THE IMMUNE TARGETS OF SWINE
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity
- A Digital Biomarker for ALS - Pison Neural Biosensor
- Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)
- Development of a novel oral brain penetrant therapeutic for ALS disease
- Engineering a Middle Meningeal Artery Embolization Model with Hydrophilicity and Hydraulic Resistance
Research funding history
16 SBIR/STTR records share this UEI (2014–2025). Reported award amounts total $7,488,575. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services